한빛사논문
- 조회498
Wonyoung Cho1, Sangil Park2,3, Hyeon Jin Kim4,5, Myeongcheol Lee4,5, Yong Sung Choi6, Seung Geun Yeo7, Jinseok Lee8, Ai Koyanagi9, Louis Jacob10, Lee Smith11, Masoud Rahmati12,13, Suhana Ahmad14, Guillaume Fond15,16, Laurent Boyer15,16, Sang Youl Rhee1,17, Seung Won Lee19, Jae Il Shin18, Ho Geol Woo2, Dong Keon Yon1,5,6
1Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea
2Department of Neurology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea
3Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
4Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea
5Department of Regulatory Science, Kyung Hee University, Seoul, South Korea
6Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea
7Department of Otolaryngology - Head & Neck Surgery, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea
8Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea
9Research and Development Unit, Parc Sanitari Sant Joan de Deu, Barcelona, Spain
10Epidemiology of Ageing and Neurodegenerative Diseases, Université Paris-Cité, Paris, France
11Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK
12Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran
13Department of Physical Education and Sport Sciences, Faculty of Literature and Humanities, Vali-E-Asr University of Rafsanjan, Rafsanjan, Iran
14Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
15Assistance Publique-Hôpitaux de Marseille (AP-HM), Aix-Marseille University, Health Service Research and Quality of Life Center, Marseille, France
16FondaMental Foundation, Creteil, France
17Department of Endocrinology and Metabolism, Kyung Hee University College of Medicine, Seoul, South Korea
18Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, South Korea
19Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea
Wonyoung Cho and Sangil Park are contributed equally.
CORRESPONDING AUTHOR : Seung Geun Yeo, Jae Il Shin, Ho Geol Woo, Dong Keon Yon
Abstract
On 23 July 2022, the World Health Organization declared the global mpox outbreak as a public health emergency of international significance. The mpox virus (MPXV) that caused the outbreak was classified as clade IIb, which belongs to the West African clade. However, the relationship between MPXV clades and symptoms, as well as the severity of mpox outcomes, is not fully understood. Thus, we aimed to investigate the global mpox prevalence and the differences in clinical manifestations and outcomes among patients with mpox between pre-outbreak (2003–2021) and the current mpox outbreak. In this systematic review and meta-analysis, PubMed/MEDLINE, Web of Science, Embase, Cumulative Index to Nursing and Allied Health Literature, and Google Scholar were searched using the keyword “monkeypox” and “mpox” up to 13 October 2022. A random effects model was used to obtain the pooled prevalence and 95% confidence intervals. This study included 27 articles, and 5698 patients with mpox with 19 distinctive features from 19 countries across five continents were assessed. Patients with mpox during the 2022 mpox outbreak showed mild clinical manifestations and outcomes compared with those before the 2022 mpox outbreak: mild rash (relative ratio [RR]: 5.09, 95% confidence interval [CI]: 1.52–17.08), fever (0.68, 0.49–0.94), pruritus (0.25, 0.19–0.32), myalgia (0.50, 0.31–0.81), headache (0.56, 0.35–0.88), skin ulcer (0.32, 0.17–0.59), abdominal symptom (0.29, 0.20–0.42), pharyngitis (0.32, 0.18–0.58), nausea or vomiting (0.15, 0.02–0.93), conjunctivitis (0.11, 0.03–0.38), concomitant infection with HIV (1.70, 0.95–3 0.04), and death (0.02, 0.001–0.31). MPXV clade IIb exhibited higher infectivity but may cause mild disease symptoms and low mortality rate. It is important to consider MPXV infection in patients with mpox-related features and/or a history of sexual transmission to prevent the spread of the disease and recognise the current pandemic threat.
논문정보
- Review Paper
- 2024년 01월 (BRIC 등록일 2024-01-02)
- 국내(교신)+국외 연구진
- 의약학 > 감염의학
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
